Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients.
about
TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traitsA comparison of methods to detect urinary tract infections using electronic data.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesDesign and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosisSystematic review of validation studies of the use of administrative data to identify serious infections.The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsHow well do discharge diagnoses identify hospitalised patients with community-acquired infections?--a validation study.A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositisRisk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.Low Completeness of Bacteraemia Registration in the Danish National Patient RegistryDerivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011.Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatmentPhysicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System.Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.Efficiency of International Classification of Diseases, Ninth Revision, billing code searches to identify emergency department visits for blood or body fluid exposures through a statewide multicenter database.Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.Validity of physician-reported hospitalized infections in a US arthritis registry.Leveraging electronic medical records for surveillance of surgical site infection in a total joint replacement population.Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.Characteristics and current practice of parenteral nutrition in hospitalized patients.Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.Bloodstream infections in patients receiving manufactured parenteral nutrition with vs without lipids: is the use of lipids really deleterious?Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs.Validation of discharge diagnosis codes to identify serious infections among middle age and older adults.
P2860
Q28545832-6829C39B-3520-4ED4-B704-284B2D60CCACQ33704169-EEC584DF-E854-482A-932A-4C12C5E0F98AQ34216770-2244C3FD-D77B-407C-9D80-04418C090CB8Q34503439-20FD085E-272C-4871-A94D-3565E5E7C03EQ34555474-FE5C864A-3BD9-4C83-B9EC-5291344B4FEBQ35082559-55B484F8-C61B-49BD-BA9C-3B67AA676CBFQ35129370-1A6F348B-B6A8-4665-9B79-1AAE72CCD82EQ35498610-0118A8F1-2F4A-4EBE-B841-D3057D191A4BQ35636624-DC2F20B4-93C8-4B9E-AE08-F73E8C621BCCQ35677387-DF7CC179-AE14-4296-8FC3-01B625F3AD58Q35840753-81119ABA-2171-4FFD-983B-DB058C8BF226Q35893859-1B58A1D5-658D-44B9-8515-4E379ACE3FD0Q35899264-6AB65C6B-2BCB-46AF-A559-29EA1F227E86Q36131029-B38A4698-2E79-407E-B9CA-5A236EEE20E2Q36150089-577F9538-00B0-4421-BC9F-E112E7E787A6Q36191250-D86085FF-EC86-46CE-BAF9-52ACB07DEF2AQ36942914-21E99F55-D359-4D13-B494-EDDCED1B303CQ37274470-AE176A22-321A-4293-B43F-EA6987F41683Q37330765-05D94A0E-11FF-4E63-94A4-7435F9347E2AQ37341114-80EBCF68-63E7-4AB1-B282-613C6F43AA78Q37347229-01452DF6-E6A2-4317-B33E-9E492945E60AQ37347648-67B913AD-A06A-4C1E-AA16-C0A193E5787BQ37860842-F7649C62-D40D-4039-9362-8C31E1CF399AQ39296189-D4AA72AE-0B84-46CC-85A8-2CC1F5F8E24EQ39626312-F80DB8FB-3359-45B1-A54B-7D341102E82EQ40242247-7BF821AE-C461-4A96-B90D-D052E3796613Q40553708-16F1A9D2-4B9A-4B6A-BEB7-F932935E8924Q40598586-2BBF4CE9-BD08-4F89-BF0B-326C0A26E9BCQ41362251-1DCF2711-271F-478B-ABCE-E042B53C14A8Q43592411-9553F24D-19DA-4553-B0A9-CFB94B9B66D0Q47574418-1FF97BEE-9297-4893-8F37-DBC241C971A5Q55297765-705B0D0C-E09B-4E78-9CB9-514063AE764C
P2860
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Administrative codes combined ...... rheumatoid arthritis patients.
@en
Administrative codes combined ...... rheumatoid arthritis patients.
@nl
type
label
Administrative codes combined ...... rheumatoid arthritis patients.
@en
Administrative codes combined ...... rheumatoid arthritis patients.
@nl
prefLabel
Administrative codes combined ...... rheumatoid arthritis patients.
@en
Administrative codes combined ...... rheumatoid arthritis patients.
@nl
P2093
P2860
P1476
Administrative codes combined ...... rheumatoid arthritis patients
@en
P2093
Carolyn Martin
Jeffrey R Curtis
Kenneth G Saag
Michael Saag
Nivedita M Patkar
P2860
P304
321-7, 327.e1-7
P356
10.1016/J.JCLINEPI.2008.06.006
P577
2008-10-01T00:00:00Z